Screener
MBX Biosciences, Inc. MBX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Proceeds from at-the-market offering, net of underwriting discounts and commissions | 85,371 | — |
| Proceeds from exercise of common stock options | 2,442 | 4 |
| Payments related to offering costs | (378) | — |
| Net cash provided by financing activities | 87,435 | 4 |
| Net decrease in cash and cash equivalents | (29,870) | (19,448) |
| Cash, cash equivalents and restricted cash, beginning of period | 75,289 | 49,351 |
| Cash, cash equivalents and restricted cash, end of period | $45,419 | $29,903 |
| Supplemental disclosure of non-cash investing and financing activities: |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s financing cash flow?
- MBX Biosciences, Inc. (MBX) reported financing cash flow of $87.44M in Q1 2026.
- How has MBX Biosciences, Inc.'s financing cash flow changed year-over-year?
- MBX Biosciences, Inc.'s financing cash flow increased by 2185775.0% year-over-year, from $4K to $87.44M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about MBX Biosciences, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude